Check out the best TED Talks below to understand the growing importance of stem cells within regenerative medicine.
In this article:
I Peace announces new iPSC lines to reduce immune rejection risk for U.S. population
More than 100 million people in the U.S. have this HLA-A haplotype
October 30, 2024, Palo Alto, CA – Leading G.M.P. cell CDMO I Peace, Inc., specializing in induced pluripotent stem cells (iPSCs) and iPSC-derived cell therapies, announced that the company has successfully generated iPS cell lines that are homozygous for HLA A, C, and DPA1. Two clonal lines are available for cell therapy developers and pharmaceutical companies as off-the-shelf products in both G.M.P. and research-grade. [Read more…]
Cell X Technologies and Aspen Neuroscience collaborate to address throughput and scalability in manufacturing automation to facilitate iPSC cell processing
Advancing the promise of cell-replacement therapy for people with Parkinson’s disease
CLEVELAND, Ohio / SAN DIEGO, Calif. – October 8, 2024 – Cell X Technologies, pioneers in automated cell processing solutions, and Aspen Neuroscience, Inc., dedicated to autologous regenerative medicine, have entered into a collaboration and licensing agreement focused on providing an automated solution for Aspen’s iPSC-derived autologous clinical manufacturing. [Read more…]
GC Therapeutics Emerges with $75M and Star-Studded Leadership to Launch Off-the-Shelf iPSC-Derived Cell Therapies at Scale
A new and highly capitalized market player has boldly declared its debut as a developer of allogeneic, off-the-shelf iPCS-derived cell therapeutics. GC Therapeutics (GCTx) has officially launched, bringing with it a revolutionary approach to cell therapy that aims to overcome current challenges in scalability, efficiency, and cost-effectiveness that have traditionally hindered the development of iPSC-derived therapies. With the debut of its innovative TFome™ platform, GCTx is positioned to scale the full potential of induced pluripotent stem cell (iPSC)-based therapies. [Read more…]
Dominance of Cellular Dynamics International (CDI) within iPSC Marketplace
Cellular Dynamics International (CDI), a FUJIFILM company, is the largest provider of induced pluripotent stem cell (iPSC) products worldwide. iPSCs are a type of laboratory made stem cell that has significant potential for use within regenerative medicine.
In theory, iPSCs have the potential to treat a wide range of diseases, including diabetes, heart diseases, autoimmune diseases, neural decline and more. iPSCs are also being widely implemented for use in drug development and discovery, as well as toxicology screening and personalized medicine.
In this article:
- Life Science Business Unit
- iPSC Market Competitors
- Cellular Dynamics International, Owned by Fujifilm Holdings
- Cellular Dynamics and Shinya Yamanaka
- An Important Player in Stem Cell Research and Therapy
- Use of iPSCs in Drug Development and Discovery
- CDI’s Acquisition by FUJIFILM Holdings Corporation
- The Future of FUJIFILM CDI
Cellular Dynamics International and iPSC Therapy
Since September 2016, Cellular Dynamics International (CDI) has been divided into two business units, a Therapeutics Business Unit and a Life Science business unit. CDI’s Therapeutics business unit is focused on developing induced pluripotent stem cell (iPSC) based therapies for ocular, cardiac, neural and oncology applications. In contrast, CDI’s Life Science business unit is focused on developing the research products side of the business.
iPSC Market Competitors
In addition to CDI, there are many other companies and organizations that are involved with the development of induced pluripotent stem cell (iPSC) therapies, including but not limited to:
- Ocata Therapeutics
- RIKEN
- Kyoto University and CiRA
- Fate Therapeutics
- Megakaryon Corporation
- Cynata Therapeutics
There are also a number of companies specializing in iPSC product development, including:
- Allele Biotechnology
- ALSTEM Bio
- Applied Biological Materials (ABM)
- Applied StemCell
- Axol Bioscience
- BrainXell
- Cell Applications
- Cellular Dynamics International (a Fujifilm Company)
- EMD Millipore
- Minerva Biotechnologies
- Ncardia (formed through merger of Axiogenesis and Pluriomics)
- Neucyte
- Pluricell Biotech
- REPROCELL
- Sigma Aldrich (provides 350 iPSC lines through partnership with EBiSC)
- STEMCELL Technologies
- Stemgent (iPS Cell Business Unit owned by ReproCELL)
- Takara Bio
- Tempo Bioscience
- Thermo Fisher Scientific
- xCell Sciences
- And others
Fujifilm Cellular Dynamics Inc.
Cellular Dynamics International is one of the most important market participants in the iPSC sector, because of its dominance in both iPSC therapies and life science tools.
- « Previous Page
- 1
- …
- 20
- 21
- 22
- 23
- 24
- …
- 79
- Next Page »